Subtype
Kidney Carcinoma
CI-CAN-00005662Explore in graph →
398 active trials17 approved drugs64 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005662Explore in graph →
Clinical trials
1,682 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01793636 | A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer(ZEBRA) | terminated | Phase 2 | 49 | Queen Mary University of LondonOTHER | 1 | Jun 24, 2014 | clinicaltrials |
| NCT00515697 | A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 18, 2014 | clinicaltrials |
| NCT01163552 | Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity | completed | Phase 2 | 5 | St. Luke's-Roosevelt Hospital CenterOTHER | 1 | Jun 13, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00918281 | Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection | completed | Phase 2 | 70 | GE HealthcareINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
| NCT01198184 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT01473043 | Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment | no longer available | — | — | PfizerINDUSTRY | 2 | May 30, 2014 | clinicaltrials |
| NCT00303862 | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00081614 | A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma | completed | Phase 2 | 100 | Genentech, Inc.INDUSTRY | 1 | May 16, 2014 | clinicaltrials |
| NCT00684996 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01711268 | Sunitinib Drug Levels and Outcomes in Kidney Cancer(CRESTO) | unknown | — | 35 | Western Sydney Local Health DistrictOTHER | 1 | May 15, 2014 | clinicaltrials |
| NCT01482520 | Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma | completed | — | 200 | Samsung Medical CenterOTHER | 1 | May 14, 2014 | clinicaltrials |
| NCT00732914 | Sequential Study to Treat Renal Cell Carcinoma | completed | Phase 3 | 272 | Sponsor GmbHOTHER | 1 | Apr 23, 2014 | clinicaltrials |
| NCT01381822 | Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors(TH-CR-410) | unknown | Phase 1 | 58 | Threshold PharmaceuticalsINDUSTRY | 1 | Apr 21, 2014 | clinicaltrials |
| NCT01449825 | Hepatic Monitoring for Pazopanib | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | Apr 21, 2014 | clinicaltrials |
| NCT00586105 | Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC) | completed | Phase 3 | 39 | BayerINDUSTRY | 2 | Apr 16, 2014 | clinicaltrials |
| NCT00353301 | Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma | completed | Phase 2 | 25 | University of Colorado, DenverOTHER | 1 | Apr 14, 2014 | clinicaltrials |
| NCT01243359 | Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies | completed | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00356460 | Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma | completed | Phase 1 | 29 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT01577784 | Pazopanib in Second-line Therapy in Renal Cell Carcinoma | unknown | Phase 2 | 27 | Associació per a la Recerca Oncologica, SpainOTHER | 1 | Mar 12, 2014 | clinicaltrials |
| NCT00348699 | AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery | completed | Phase 1 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT01836406 | Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy | completed | N/A | 16 | Yonsei UniversityOTHER | 1 | Feb 19, 2014 | clinicaltrials |
| NCT00891475 | Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients | completed | Phase 1 / Phase 2 | 114 | Kidney Cancer Research BureauOTHER | 1 | Feb 13, 2014 | clinicaltrials |
| NCT00523640 | A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 30 | University of ChicagoOTHER | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00073307 | Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer | completed | Phase 3 | 903 | BayerINDUSTRY | 19 | Feb 6, 2014 | clinicaltrials |
| NCT00980213 | Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland | completed | — | 80 | Pirkko-Liisa Kellokumpu-LehtinenOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT02056587 | Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment | completed | Phase 4 | 37 | Kidney Cancer Research BureauOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00942058 | Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer(CA9CRM) | terminated | — | 16 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jan 29, 2014 | clinicaltrials |
| NCT01677390 | A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma | terminated | Phase 1 | 4 | Seagen Inc.INDUSTRY | 1 | Jan 28, 2014 | clinicaltrials |
| NCT00387764 | Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer | completed | Phase 3 | 80 | GlaxoSmithKlineINDUSTRY | 20 | Jan 14, 2014 | clinicaltrials |
| NCT00718367 | Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens | completed | — | — | National University Hospital, SingaporeOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00836745 | Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent | completed | — | 36 | PfizerINDUSTRY | 1 | Dec 20, 2013 | clinicaltrials |
| NCT00586495 | Long-term Extension From RCC Phase II (11515) | completed | Phase 2 | 95 | BayerINDUSTRY | 1 | Dec 13, 2013 | clinicaltrials |
| NCT00602862 | Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 | completed | N/A | 26 | Radboud University Medical CenterOTHER | 1 | Dec 2, 2013 | clinicaltrials |
| NCT00474786 | Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib(INTORSECT) | completed | Phase 3 | 512 | PfizerINDUSTRY | 20 | Nov 21, 2013 | clinicaltrials |
| NCT00876382 | Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma | completed | — | 47 | SCRI Development Innovations, LLCOTHER | 1 | Nov 14, 2013 | clinicaltrials |
| NCT01063998 | A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma | terminated | — | 23 | Jason HafronOTHER | 1 | Nov 8, 2013 | clinicaltrials |
| NCT00110344 | Research Study for Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 1 | BayerINDUSTRY | 1 | Oct 11, 2013 | clinicaltrials |
| NCT01100619 | A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors | completed | Phase 1 | 40 | ExelixisINDUSTRY | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00203866 | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 40 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00059813 | Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00557830 | Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 12 | Accelerated Community Oncology Research NetworkOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00678119 | Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment | completed | Phase 2 | 25 | Argos TherapeuticsINDUSTRY | 2 | Jul 15, 2013 | clinicaltrials |
| NCT01079286 | Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers(I-NET) | completed | Phase 1 | 18 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 15, 2013 | clinicaltrials |
| NCT00040989 | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00502034 | Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. | completed | Phase 3 | 310 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01073644 | Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients | terminated | — | 3 | PfizerINDUSTRY | 1 | Jul 4, 2013 | clinicaltrials |
| NCT01892059 | Study of Segmental Renal Artery Clamping During Laparoscopic Partial Nephrectomy | unknown | N/A | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 3, 2013 | clinicaltrials |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jun 24, 2014source: clinicaltrials